TG Therapeutics Q2 2026 earnings preview shows consensus EPS of $0.44 and revenue of $229.79M

Seeking Alpha··Read original
2▲0 ▼0Impact / 5
Summary · why it matters

TG Therapeutics is scheduled to announce its second-quarter 2026 earnings results on Monday, August 3rd, before market open. The consensus earnings per share estimate stands at $0.44, while the consensus revenue estimate is $229.79 million, representing a 62.8% increase year-over-year. Over the last three months, EPS estimates have seen four upward revisions and one downward revision, and revenue estimates have seen seven upward revisions with no downward revisions.

Impact on assets 1

Biotech & Genomic Medicine▲ · 1 stocks
TG Therapeutics Inc
TGTX
± MixedCapitalrelevance

Earnings preview with consensus estimates; actual results unknown, so impact is uncertain.

© 2026 MarketIVNews